Latest in Cardiology from ACC.org

• Oral, Subcutaneous Amycretin Similarly Safe, Tolerated as GLP-1 Monoagonists
  Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist has a safety and tolerability profile similar with other GLP-1 and amylin agonists in both oral and subcutaneous formulations, according to two studies published in The Lancet.
• CAPLA: Long-Term QOL Improvement With CA For Persistent AFib
  Quality of life (QOL) at three years significantly improved following catheter ablation (CA) for persistent atrial fibrillation (PsAFib), according to a secondary analysis of patients in the CAPLA clinical trial published in JACC: Clinical Electrophysiology.
• Thrombotic Events In ATTR-CM Patients Linked to Primary LA Cardiopathy
  Primary left atrial (LA) cardiopathy appears to be linked to the high risk of thrombotic events (TE) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) independent of atrial fibrillation (AFib), CHA2DS2-VASc score and LA dilatation. This link differs from patients with other left ventricular hypertrophy (LVH) phenotypes according to a new study published in JACC: Cardiovascular […]
• REDEFINE 1 and REDEFINE 2: Greater Weight Loss With Combined Cagrilintide-Semaglutide vs. Either Drug Alone or Placebo
  The combination of cagrilintide with semaglutide (CagriSema) in a single weekly injection was associated with a significantly greater weight loss in adults with overweight or obesity regardless of type 2 diabetes (T2D) status compared with placebo or either drug alone...
• Starting DOACs Early After Stroke Lowers Risk of Future Strokes, Hemorrhage
  Initiating direct oral anticoagulants (DOACs) within four days, rather than at five days or later, after an ischemic stroke in patients with atrial fibrillation (AFib) reduced the risk of future stroke events within 30 days without increasing symptomatic intracerebral hemorrhage...